Media coverage about Clementia Pharmaceuticals (NASDAQ:CMTA) has been trending somewhat positive on Thursday, Accern Sentiment reports. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Clementia Pharmaceuticals earned a news impact score of 0.14 on Accern’s scale. Accern also gave news articles about the company an impact score of 47.5967695714722 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the media stories that may have effected Accern’s rankings:
- Clementia Pharma completes enrollment in late-stage study of paloverotene in FOP (seekingalpha.com)
- Clementia Announces Completion of Enrollment in Phase 3 MOVE Trial for FOP (finance.yahoo.com)
- Clementia Pharmaceuticals (CMTA) Price Target Cut to $16.00 (americanbankingnews.com)
- Clementia Pharmaceuticals (CMTA) PT Lowered to $26.00 at Morgan Stanley (americanbankingnews.com)
- Clementia Pharmaceuticals (CMTA) Announces Quarterly Earnings Results (americanbankingnews.com)
NASDAQ:CMTA traded up $1.42 during mid-day trading on Thursday, reaching $9.88. The company’s stock had a trading volume of 90,076 shares, compared to its average volume of 79,056. Clementia Pharmaceuticals has a 12-month low of $8.10 and a 12-month high of $20.15. The firm has a market cap of $285.46 million and a price-to-earnings ratio of -1.25.
A number of equities analysts have weighed in on CMTA shares. ValuEngine raised Clementia Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Zacks Investment Research lowered Clementia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, May 14th. Wedbush reissued an “outperform” rating and issued a $26.00 target price on shares of Clementia Pharmaceuticals in a research report on Friday, August 10th. Morgan Stanley decreased their target price on Clementia Pharmaceuticals from $27.00 to $26.00 and set an “overweight” rating for the company in a research report on Monday. Finally, B. Riley decreased their target price on Clementia Pharmaceuticals from $25.00 to $16.00 and set a “buy” rating for the company in a research report on Wednesday. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $24.60.
Clementia Pharmaceuticals Company Profile
Clementia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial.
Further Reading: Dividend Stocks – Are They Right For You?
Receive News & Ratings for Clementia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.